- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.09. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update | 261 | PR Newswire | A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed... ► Artikel lesen | |
| 20.08. | Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution | 2 | Investing.com | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Brookline Capital upgrades Intensity Therapeutics stock rating to Buy | 3 | Investing.com | ||
| 12.08. | Intensity Therapeutics regains compliance with Nasdaq requirement | 2 | Seeking Alpha | ||
| 12.08. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement | 144 | PR Newswire | SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 08.08. | Intensity Therapeutics GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 07.08. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 88 | PR Newswire | Over $11 million raised since the beginning of 2Q 2025
Cash runway extended into the second half of 2026
In the INVINCIBLE-4 Study, patients receiving INT230-6... ► Artikel lesen | |
| 07.08. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.08. | Intensity Therapeutics raises $6.6M via at-the-market offering | 2 | Seeking Alpha | ||
| 18.07. | Intensity Therapeutics: Aktionäre bestätigen Direktor und Wirtschaftsprüfer | 2 | Investing.com Deutsch | ||
| 18.07. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Intensity Therapeutics: INT230-6 Achieves Complete Responses In Murine Models Of MPNST | 1 | RTTNews | ||
| 30.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) | 141 | PR Newswire | SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 27.06. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.06. | Intensity Therapeutics shares plummet on proposed public offering | 3 | Seeking Alpha | ||
| 11.06. | Intensity Therapeutics kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 11.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase ... | 345 | PR Newswire | SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,30 | -0,42 % | BioNTech SE: BioNTech veranstaltet am 1. Oktober 2025 zweiten "AI Day" als eine Ausgabe der "Innovation Series" | MAINZ, Deutschland, 23. September 2025("InstaDeep"), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten "AI Day" aus, eine Ausgabe von BioNTechs "Innovation Series"... ► Artikel lesen | |
| NOVAVAX | 7,227 | -1,18 % | Milliarden-Verlustgefahr: Nach zweistelligem Absturz: Warum Novavax-Investoren weiter zittern müssen | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenNovavax steht unter massivem Druck: Ein Analysten-Downgrade, neue Milliarden-Schulden und Zweifel an der Impfstoff-Zukunft haben die Aktie... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 54,00 | -0,92 % | Morningstar Launches New Benchmark and Expands with CRSP Acquisition | ||
| EDITAS MEDICINE | 2,950 | -1,60 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,200 | -0,88 % | Ginkgo Bioworks Reports Second Quarter 2025 Financial Results | Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets
BOSTON, Aug. 7, 2025 /PRNewswire/ --... ► Artikel lesen | |
| NOVOCURE | 10,980 | -0,32 % | Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting | METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,120 | 0,00 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
| ADVERUM BIOTECHNOLOGIES | 3,760 | +4,44 % | Mizuho reiterates Outperform rating on Adverum stock amid positive trial updates | ||
| ARCUTIS BIOTHERAPEUTICS | 18,620 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| QIAGEN | 37,620 | +0,28 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 6,245 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| IMMUNOVANT | 16,060 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| NUVALENT | 84,84 | +4,24 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 42,655 | -0,69 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 6,070 | +2,33 % | Evotec-Aktie leicht im Minus (6,156 €) | Am deutschen Aktienmarkt notiert das Wertpapier von Evotec aktuell etwas leichter. Der jüngste Kurs betrug 6,16 Euro. Ein Verlust von 2,75 Prozent steht gegenwärtig für der Anteilsschein von Evotec... ► Artikel lesen |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,246 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.